The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures
Abstract
BACKGROUND: Zonisamide is a sulfonamide antiepilepsy drug with sodium and calcium channel-blocking actions. Experience in Japan and a previous European double-blind study have demonstrated its efficacy against partial-onset seizures. METHODS: A randomized, double-blind, placebo-controlled trial enrolling 203 patients was conducted at 20 United States sites to assess zonisamide efficacy and dose response as adjunctive therapy for refractory partial-onset seizures. Zonisamide dosages were elevated by 100 mg/d each week. The study design allowed parallel comparisons with placebo for three dosages and a final crossover to 400 mg/d of zonisamide for all patients. The primary efficacy comparison was change in seizure frequency from a 4-week placebo baseline to weeks 8 through 12 on blinded therapy. RESULTS: At 400 mg/d, zonisamide reduced the median frequency of all seizures by 40.5% from baseline, compared with a 9% reduction (p = 0.0009) with placebo treatment, and produced a > or =50% seizure reduction (responder rate) in 42% of patients. A dosage of 100 mg/d produced a 20.5% reduction in median seizure frequency (p = 0.038 compared with placebo) and a dosage of 200 mg/d produced a 24.7% reduction in median seizure frequency (p = 0.004 compared with placebo). Dropouts from adverse events (10%) did not differ from placebo (8.2%, NS). The only adverse event differing significantly from placebo was weight loss, though somnolence, anorexia, and ataxia were slightly more common with zonisamide treatment. Serum zonisamide concentrations rose with increasing dose. CONCLUSION: Zonisamide is effective and well tolerated as an adjunctive agent for refractory partial-onset seizures. The minimal effective dosage was 100 mg/d, but 400 mg/d was the most effective dosage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improving the Quality of Reporting of Randomized Controlled Trials: The CONSORT Statement
Begg, C. (1996) · JAMA · doi:10.1001/jama.1996.03540080059030 · Cited by 3,127
Cited by
French, J. A., Kanner, A. M., Bautista, J., Abou-Khalil, B., Browne, T., Harden, C. L., Theodore, W. H., Bazil, C., Stern, J., Schachter, S. C., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000123693.82339.fc · Cited by 654
Self-citationRefractory Epilepsy: Clinical Overview
French, J. A. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2007.00992.x · Cited by 430
Role of oxidative stress in epileptic seizures
Shin, E.-J., Jeong, J. H., Chung, Y. H., Kim, W.-K., Ko, K.-H., Bach, J.-H., Hong, J.-S., Yoneda, Y., & Kim, H.-C. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2011.03.025 · Cited by 422
Intractable epilepsy: management and therapeutic alternatives
Schuele, S. U., & Lüders, H. O. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70108-x · Cited by 344
Negative Effects of Antiepileptic Drugs on Mood in Patients with Epilepsy
Mula, M., & Sander, J. W. (2007) · Drug Safety · doi:10.2165/00002018-200730070-00001 · Cited by 306
Metadata
- Authors
- Faught, E., Ayala, R., Montouris, G. G., Leppik, I. E., & the Zonisamide 922 Trial Group
- Venue
- Neurology
- Published
- 2001-11-27
- Volume
- 57
- Issue
- 10
- Pages
- 1774-1779
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2099686832
- Cited by
- 222
- References
- 1
- FWCI
- 8.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. https://app.cochat.ai/papers/10.1212/wnl.57.10.1774
- The paper
- Faught, E., Ayala, R., Montouris, G. G., Leppik, I. E., & the Zonisamide 922 Trial Group. (2001). Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology. https://doi.org/10.1212/wnl.57.10.1774
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.